This article was originally published here
Diabetes Ther. 2021 March 10th doi: 10.1007 / s13300-021-01038-6. Online before printing.
ABSTRACT
INTRODUCTION: Understanding comorbid conditions with type 2 diabetes mellitus (T2DM) is critical to clinical decision-making in the choice of pharmacotherapy. This study aimed to describe the prevalence and co-prevalence of comorbidities, including chronic kidney disease (CKD) and cardiovascular disease (CVD) (coronary artery disease (CAD), cerebrovascular disease, peripheral arterial disease (PAD), and heart failure ( CHF))) in patients with T2DM.
METHODS: A multicenter, cross-sectional, observational study of 300 patients with T2DM. The data was collected from patient records during the registration visit.
Results: A total of 38%, 10% and 2% of the patients had one, two and three comorbidities, respectively, with the number of comorbidities increasing significantly with age. The most common comorbidities were CVD (17.3%), CAD (15%) and CKD (44.3%), mostly stages 2 and 3. The prevalence of CHF (0.7%), PAD (2.3%) and cerebrovascular disease (1.3%) was low. The highest percentage of antihyperglycemics used was metformin (81%), dipeptidyl peptidase-4 inhibitors (46%), sodium glucose co-transporter-2 inhibitors (37%), insulin (36%) and sulfonylurea (34%). . The choice of antihyperglycemic class did not change between age groups and gender.
Conclusion: Half of the patients only had T2DM. The most frequently observed comorbidity was CRF, mainly stage 2. The incidence of comorbidity tended to increase significantly in older age groups.
PMID: 33694092 | DOI: 10.1007 / s13300-021-01038-6
